Sargramostim Plasmid DNA Melanoma Vaccine Adjuvant
nci:P207
C0393071
nci:P303
Melanoma.
nci:P329
42679
nci:P330
42679
nci:P366
Sargramostim_Plasmid_DNA_Melanoma_Vaccine
nci:P90
<n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>GM-CSF plasmid DNA melanoma vaccine</n0:term-name><n0:term-group>SY</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm><n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>Sargramostim Plasmid DNA Melanoma Vaccine Adjuvant</n0:term-name><n0:term-group>PT</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm>
nci:P97
<n0:ComplexDefinition xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:def-definition>A vaccine adjuvant consisting of a plasmid DNA encoding sargramostim (a granulocyte macrophage-colony stimulating factor). Upon administration, expressed sargramostim may stimulate a cytotoxic T cell response enhancing the host immune response to a concomitantly administered melanoma vaccine.</n0:def-definition><n0:def-source>NCI</n0:def-source></n0:ComplexDefinition>